Moderna, Inc.
NASDAQ:MRNABiotechnology
+$2.48 today
- Market cap
- $79.63B
- Beta
- 1.03
- P/E (TTM)
- -7.9
- EPS (TTM)
- -$8.09
Volume 6.91M
Average 6.53M
MRNA Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Moderna, Inc.NASDAQ: MRNA
Cash & Equivalents · Q3 FY2026 · quarter ended Sep 2026
Cash & equivalents rises 5.6% from a year ago
Cash & equivalents stood at $1.2B at the end of Q3 FY2026, up 5.6% from a year earlier and down 30.6% from the prior quarter. Over 3 fiscal years it compounded at -6.8% a year.
Context
- Cash & equivalents amounted to 8.9% of total assets at the end of Q3 FY2026, down 0.5 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +5.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 2.6B USD
- Year-over-year change
- +34.7%
- 4-year CAGR
- -21.5%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.6B | +34.7% |
| FY2024 | 2024-12-31 | 1.93B | -33.7% |
| FY2023 | 2023-12-31 | 2.91B | -9.3% |
| FY2022 | 2022-12-31 | 3.21B | -53.2% |
| FY2021 | 2021-12-31 | 6.85B | — |
Cash & Equivalents vs competitors
How MRNA compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +5.6% is the highest of 10, against a peer median of -31.1%.
- Cash & equivalents amounts to 8.9% of total assets for MRNA, versus a peer median of 26.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | €9.74B EUR | -5.2% | -17.9% | 47.9% | |
| Jun 2026 | £3.09B GBP | -37.4% | -3.1% | 5.0% | |
| Sep 2026 | $1.2B USD | +5.6% | -6.8% | 8.9% | |
| Jun 2026 | $976M USD | -40.4% | +40.0% | 0.5% | |
| Mar 2026 | $276.09M USD | +0.9% | -34.9% | 26.9% | |
| Mar 2026 | $228.36M USD | -13.3% | -43.5% | 21.9% | |
| Mar 2026 | $211.38M USD | -2.6% | -16.2% | 86.1% | |
| Jun 2026 | $183.19M USD | -40.3% | -40.7% | 5.8% | |
| Mar 2026 | €105.37M EUR | -31.1% | -27.6% | 28.3% | |
| Mar 2026 | $26.27M USD | -34.2% | -1.5% | 52.8% | |
| Peer median (excluding MRNA) | — | -31.1% | -17.9% | 26.9% | |
Competitors are the stored peer set for MRNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 6.85B | 3.21B | 2.91B | 1.93B | 2.6B |
| Short-term Investments | 3.88B | 6.7B | 5.7B | 5.1B | 3.2B |
| Net Receivables | 3.32B | 1.69B | 1.08B | 592M | 284M |
| Inventory | 1.44B | 949M | 202M | 117M | 153M |
| Other Current Assets | 26M | 44M | 88M | 58M | 45M |
| Total Current Assets | 16.07B | 13.43B | 10.33B | 8.1B | 6.54B |
| Property, Plant & Equipment (Net) | 1.38B | 2.14B | 2.66B | 2.96B | 2.85B |
| Goodwill | 0 | 0 | 52M | 52M | 52M |
| Intangible Assets | 0 | 0 | 44M | 40M | 45M |
| Long-term Investments | 6.84B | 8.36B | 4.74B | 2.51B | 2.34B |
| Tax Assets | 326M | 982M | 81M | 81M | 81M |
| Other Non-current Assets | 46M | 946M | 523M | 407M | 421M |
| Total Non-current Assets | 8.6B | 12.43B | 8.1B | 6.04B | 5.79B |
| Total Assets | 24.67B | 25.86B | 18.43B | 14.14B | 12.34B |
| Account Payables | 302M | 487M | 520M | 405M | 317M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 876M | 48M | 63M | 3M | 0 |
| Deferred Revenue | 6.25B | 2.04B | 568M | 153M | 99M |
| Other Current Liabilities | 140M | 243M | 842M | 863M | 1.57B |
| Total Current Liabilities | 9.13B | 4.92B | 3.02B | 2.21B | 1.99B |
| Long-term Debt | 0 | 0 | 0 | 0 | 1.24B |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 615M | 673M | 83M | 58M | 153M |
| Other Non-current Liabilities | 76M | 135M | 256M | 267M | (368M) |
| Total Non-current Liabilities | 1.4B | 1.81B | 1.56B | 1.04B | 1.7B |
| Total Liabilities | 10.52B | 6.74B | 4.57B | 3.24B | 3.69B |
| Common Stock | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | 9.96B | 18.32B | 13.61B | 10.05B | 7.22B |
| Accumulated OCI | (24M) | (370M) | (123M) | (10M) | 45M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 14.15B | 19.12B | 13.85B | 10.9B | 8.65B |
| Total Debt | 916M | 1.2B | 1.24B | 747M | 1.92B |
| Net Debt | (5.93B) | (2.01B) | (1.66B) | (1.18B) | (679M) |
Moderna, Inc.
NASDAQ:MRNA
Intrinsic Alpha fair value
Locked
Current Price
$196.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.